Browse the full directors' dealings record of Rayonier Advanced Materials INC., a listed issuer based in United States. Shares are listed on US US, under the authority of SEC (Form 4). Operating in the Chemicals & Materials sector, Rayonier Advanced Materials INC. has logged 51 public disclosures. Market capitalisation: €588.1m. The latest transaction was filed on 15 May 2026 — Levée d'options. Among the most active insiders: Dill Julie. Every trade is openly available.
25 of 51 declarations
Rayonier Advanced Materials Inc. (RYAM) is a U.S.-listed company traded on the NYSE/NASDAQ market in the United States, with its corporate headquarters in Jacksonville, Florida. The company is a global leader in cellulose and derivatives, serving technically demanding end markets such as filters, food, pharmaceuticals, high-performance plastics, propellants, and other industrial applications. Its operating heritage dates back more than 95 years, reflecting a long industrial lineage in wood-based and pulp-related materials. ([investors.ryam.com](https://investors.ryam.com/overview/default.aspx)) RYAM’s business model is centered on specialized cellulose products rather than broad commodity chemicals. Its main product families include cellulose specialties, cellulose commodities, cellulose viscose pulp, cellulose fluff pulp, high-yield pulp, and value-added derivatives such as paperboard, biofuels, bioelectricity, and lignin. The company also describes biomaterials as an important growth vector, as it seeks to expand into renewable, higher-value applications. Manufacturing assets are located in the United States, Canada, and France, and the company sells into more than 40 countries, giving it a genuinely international footprint. ([investors.ryam.com](https://investors.ryam.com/overview/default.aspx)) From a competitive standpoint, RYAM occupies a specialist niche with meaningful technical barriers. Its position is supported by dedicated industrial capacity, process know-how in high-purity cellulose, and diversified downstream uses that touch consumer, pharmaceutical, and industrial supply chains. This niche positioning can support pricing power in certain products, but the business remains exposed to raw-material inflation, logistics costs, cyclical demand patterns, and trade-policy volatility. The company explicitly highlights tariff and cross-border trade risks, particularly involving China, Canada, and Mexico. ([investors.ryam.com](https://investors.ryam.com/files/doc_financials/2024/ar/2025-03-28_2024_Annual_Report_-_Final_for_webhosting.pdf)) Recent developments point to an ongoing portfolio transition. RYAM reported 2025 revenue of $1.5 billion, adjusted EBITDA of $133 million, and adjusted net debt of about $745 million at year-end 2025. Management also described 2025 as a challenging year, with mixed demand conditions and segment restructuring within High Purity Cellulose. A key operational event was the indefinite suspension of the Temiscaming plant in July 2024, followed by the permanent cessation of DWP production in the first quarter of 2026. In parallel, RYAM continues to invest in biomaterials, including projects in France, as it works to diversify earnings and strengthen long-term profitability. ([investors.ryam.com](https://investors.ryam.com/overview/default.aspx))